Currently out of the existing stock ratings of Matthew Sharpe, 21 are a HOLD (41.18%), 3 are a SELL (5.88%), 27 are a BUY (52.94%).

Matthew Sharpe

Work Performance Price Targets & Ratings Chart

Analyst Matthew Sharpe, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 86.67% that have a potential upside of 22.76% achieved within 250 days.

Matthew Sharpe’s has documented 117 price targets and ratings displayed on 12 stocks. The coverage is on Industrials, Technology sectors.

Most recent stock forecast was given on PL, Planet Labs PBC at 12-Jun-2023.

Wall Street Analyst Matthew Sharpe

Analyst best performing recommendations are on MAXR (MAXAR TECHNOLOGIES).
The best stock recommendation documented was for MAXR (MAXAR TECHNOLOGIES) at 12/14/2022. The price target of $42 was fulfilled within 2 days with a profit of $17.96 (74.71%) receiving and performance score of 373.54.

Average potential price target upside

of $30.85 (11.1%) on CACI (CACI INTERNATIONAL).
of $17.65 (66.5%) on MAXR (MAXAR TECHNOLOGIES).
of $16.18 (20.33%) on BAH (BOOZ ALLEN HAMILTON).

BAH Booz Allen Hamilton CACI CACI International LDOS Leidos Holdings MANT ManTech International MAXR Maxar Technologies MEG Montrose Environmental Grp PAE PAE PSN Parsons Corp SAIC Science Applications International Corp PRIM Primoris Services PRSP Perspecta PL Planet Labs PBC

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score